Details for New Drug Application (NDA): 215158
✉ Email this page to a colleague
NDA 215158 describes CHLORZOXAZONE, which is a drug marketed by Acme Labs, Actavis Elizabeth, Ajenat Pharms, Aurobindo Pharma Ltd, Barr, Chartwell Rx, Corepharma, Dr Reddys Labs Sa, Endo Operations, Glenmark Pharms Ltd, Mikart, Novitium Pharma, Ohm Labs, Pioneer Pharms, Rising, Senores Pharms, Strides Pharma, Sun Pharm Industries, Teva Pharms Usa Inc, Upsher Smith Labs, and Watson Labs, and is included in thirty-five NDAs. It is available from eighteen suppliers. Additional details are available on the CHLORZOXAZONE profile page.
The generic ingredient in CHLORZOXAZONE is chlorzoxazone. There are sixteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the chlorzoxazone profile page.
The generic ingredient in CHLORZOXAZONE is chlorzoxazone. There are sixteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the chlorzoxazone profile page.
Summary for 215158
| Tradename: | CHLORZOXAZONE |
| Applicant: | Senores Pharms |
| Ingredient: | chlorzoxazone |
| Patents: | 0 |
Pharmacology for NDA: 215158
| Physiological Effect | Centrally-mediated Muscle Relaxation |
Medical Subject Heading (MeSH) Categories for 215158
Suppliers and Packaging for NDA: 215158
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| CHLORZOXAZONE | chlorzoxazone | TABLET;ORAL | 215158 | ANDA | Cintex Services, LLC | 24470-923 | 24470-923-10 | 100 TABLET in 1 BOTTLE (24470-923-10) |
| CHLORZOXAZONE | chlorzoxazone | TABLET;ORAL | 215158 | ANDA | Cintex Services, LLC | 24470-923 | 24470-923-60 | 60 TABLET in 1 BOTTLE (24470-923-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 250MG | ||||
| Approval Date: | Jul 29, 2021 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
